Published in Blood Weekly, January 12th, 2006
"We analyzed the impact of alloSCT as an early consolidation for young patients with acute myeloblastic leukemia in first complete remission (CR1) through four successive protocols. Of the 472 patients who achieved CR1, 182 (38%) had an HLA-identical sibling (donor group), and alloSCT was performed in 171 patients (94%). Of the 290 patients without donor (no-donor group), 62% received an autologous SCT," scientists in France reported.
"In an intent-to-treat analysis based on donor availability, the overall 10-year survival...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.